Freshly prepared 0.1% nanoparticle curcumin mouthwash × Prevention of oral-mucositis severity during head-and-neck radiotherapy

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Evidence conditionWhich mouthwash and mucositis question is presented?Required	The original question concerns prevention of oral-mucositis severity during head-and-neck radiotherapy. Onset results from the same trial remain separate supportive information. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Intervention, population, severity, time, active comparator and original claim	Material needed: Original-trial question, eligibility and endpoint plans. This records needed materials; no new research was executed.
2	Partly verified	Full text not readStored summary read	N02 · Evidence conditionWhat is the 0.1% nanocurcumin mouthwash?Required	The record describes freshly prepared daily 0.1% mouthwash. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Curcuma longa-derived curcumin nanoparticles and freshly prepared 0.1% mouthwash	Material needed: Formulation composition, nanoparticle characteristics, batch analyses and preparation procedures. This records needed materials; no new research was executed.
3	Partly verified	Full text not readStored summary read	N03 · Evidence conditionAre rinse-and-spit use and other oral products distinguished?Required	The route is topical oral rinsing followed by spitting. The original record warns against treating swallowed formulations and topical products as interchangeable. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	The topical oral rinse-and-spit route	Material needed: Rinse-use procedures and exposure records. This records needed materials; no new research was executed.
4	Partly verified	Full text not readStored summary read	N04 · Evidence conditionWhich radiotherapy population is included?Required	The retained population is adults receiving head-and-neck radiotherapy. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Eligibility and baseline conditions of adults receiving head-and-neck radiotherapy	Material needed: Eligibility, baseline-characteristic and radiotherapy-population tables. This records needed materials; no new research was executed.
5	Unverified	Full text not readStored summary read	N05 · Evidence conditionWhat were the radiation dose, chemotherapy and oral-care differences?Required	The original material limits the comparison to treatment during radiotherapy. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Radiotherapy schedules/cumulative doses, concurrent anticancer treatment and basic oral care	Material needed: Group cancer-treatment, oral-care and rescue-medication tables. This records needed materials; no new research was executed.
6	Partly verified	Full text not readStored summary read	N06 · Evidence conditionWhat was compared with benzydamine?Required	The retained direct comparison is 0.1% nanocurcumin versus 0.15% benzydamine for 6 weeks. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Actual use of 0.15% benzydamine mouthwash	Material needed: Control-use procedures and care common to both groups. This records needed materials; no new research was executed.
7	Partly verified	Full text not readStored summary read	N07 · Evidence conditionWhat were the actual volume and frequency for the 0.1% rinse?Required	The record describes 0.1% mouthwash, with volume and frequency following the original trial procedures. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Concentration, volume per 1 rinse, daily frequency and exposure time	Material needed: Trial rinse procedures and use diaries. This records needed materials; no new research was executed.
8	Partly verified	Full text not readStored summary read	N08 · Evidence conditionHow was quality maintained for freshly prepared daily mouthwash?Required	The record describes freshly prepared daily nanoparticle mouthwash and limited contamination-control material. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Preparation, storage, expiry, contamination control and quality tracking	Material needed: Preparation SOPs, stability and microbial/quality records. This records needed materials; no new research was executed.
9	Partly verified	Full text not readStored summary read	N09 · Evidence conditionWhen during the 6 weeks were treatment and assessments performed?Required	The retained duration is 6 weeks during radiotherapy. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Initiation, radiotherapy schedules, visit assessments and completion/discontinuation	Material needed: Trial visit/treatment schedules and follow-up plans. This records needed materials; no new research was executed.
10	Partly verified	Full text not readStored summary read	N10 · Evidence conditionAre WHO severity and mucositis onset the same outcome?Required	WHO oral-mucositis occurrence/severity is the selected question; delayed onset is described as a separate supportive result. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Distinguishing WHO severity/occurrence from time to onset	Material needed: Endpoint definitions, analysis plans and result tables. This records needed materials; no new research was executed.
11	Partly verified	Full text not readStored summary read	N11 · Evidence conditionWhich WHO grades were dichotomized as severe?Required	Severe oral-mucositis occurrence/severity by WHO criteria and a dichotomized severe-outcome comparison are mentioned. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	WHO grades, severity cutoff, assessors and repeated measurement	Material needed: WHO grading criteria, assessor guidance and visit tables. This records needed materials; no new research was executed.
12	Unverified	Full text not readStored summary read	N12 · Evidence conditionWhich endpoint was prespecified as primary (1st)?Required	The retained record labels the WHO-severity endpoint as primary. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Registration, protocol, SAP and endpoint/analysis hierarchy	Material needed: Original CTRI registration, dated plans and SAP. This records needed materials; no new research was executed.
13	Partly verified	Full text not readStored summary read	N13 · Evidence conditionWhat denominator does 74 represent?Required	The retained evidence describes 74 randomized participants. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Distinguishing randomized, group-allocation, analysis and completion denominators	Material needed: CONSORT flow and group-allocation/analysis tables. This records needed materials; no new research was executed.
14	Unverified	Full text not readStored summary read	N14 · Evidence conditionWho was included in mITT and what did it estimate?Required	The design mentions mITT and PP; the retained explanation describes an mITT onset HR signal. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	mITT inclusion conditions, exclusions, group counts and target effects	Material needed: mITT definitions, flow and endpoint-specific result tables. This records needed materials; no new research was executed.
15	Unverified	Full text not readStored summary read	N15 · Evidence conditionHow did PP results and denominators differ from mITT?Required	Only the description that the trial included PP remains in the record. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	PP adherence criteria, denominators and severity/onset results	Material needed: PP definitions, analysis and attrition tables. This records needed materials; no new research was executed.
16	Partly verified	Full text not readStored summary read	N16 · Evidence conditionWhat was the between-group result for severe-mucositis prevention?Required	The original narrative describes no significant difference in the dichotomized severe outcome and no evidence of better severity prevention than benzydamine. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Severe events/denominators, between-group effects, CIs and timepoints	Material needed: WHO-severity result tables and analysis output. This records needed materials; no new research was executed.
17	Partly verified	Full text not readStored summary read	N17 · Evidence conditionWhat do the onset HR of approximately 0.5 and delay of about 2 weeks mean?Required	The retained result describes delayed onset with an HR of approximately 0.5; the original summary describes onset about 2 weeks later. The mITT onset signal remains distinct from WHO severity. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Definitions, units, denominators and CIs for time-to-onset results	Material needed: Onset curves, hazard analyses and timing tables. This records needed materials; no new research was executed.
18	Unverified	Full text not readStored summary read	N18 · Evidence conditionHow were onset assessment intervals, censoring and follow-up handled?Required	The original material describes a 6-week duration and an onset HR signal. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Assessment intervals, censoring, event times and radiotherapy exposure	Material needed: Onset statistical methods and individual timing/follow-up material. This records needed materials; no new research was executed.
19	Partly verified	Full text not readStored summary read	N19 · Evidence conditionDoes no significant difference establish equivalence?Required	The original record says superiority and equivalence were not established and complete ineffectiveness cannot be concluded. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Superiority/noninferiority/equivalence designs, margins and CIs	Material needed: Trial hypotheses, margins and effect intervals. This records needed materials; no new research was executed.
20	Unverified	Full text not readStored summary read	N20 · Evidence conditionHow were random sequences and allocation concealment implemented?Required	The retained descriptions identify a pilot RCT and 74 randomized participants. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Sequence generation, allocation concealment and baseline balance	Material needed: Randomization procedures and baseline tables. This records needed materials; no new research was executed.
21	Unverified	Full text not readStored summary read	N21 · Evidence conditionWhat did triple blinding and blinded WHO assessment cover?Required	The study title and design describe a triple-blind pilot RCT. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Participant, provider and assessor blinding, and distinguishability of the rinses	Material needed: Blinding procedures, product appearance and assessor guidance. This records needed materials; no new research was executed.
22	Unverified	Full text not readStored summary read	N22 · Evidence conditionWhat were rinse adherence and treatment deviations?Required	The retained record describes a 6-week rinse comparison and mITT/PP analyses. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Use diaries, nonuse, crossover, radiotherapy interruption and rescue treatment	Material needed: Use diaries, discontinuation reasons and analysis plans. This records needed materials; no new research was executed.
23	Unverified	Full text not readStored summary read	N23 · Evidence conditionWhich participants had missing outcome data?Required	The original record describes 74 randomized participants and an mITT/PP design. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Group missingness/attrition, reasons, handling and sensitivity analyses	Material needed: Group flow, missing-data handling and sensitivity tables. This records needed materials; no new research was executed.
24	Unverified	Full text not readStored summary read	N24 · Evidence conditionHow did registration plans correspond to reported results?Required	The citation lists CTRI/2018/04/013362, while the original trial-registration field says unverified. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	CTRI, protocol, SAP and all planned endpoints/analyses	Material needed: Registration history, protocol, SAP and complete endpoint tables. This records needed materials; no new research was executed.
25	Unverified	Full text not readStored summary read	N25 · Evidence conditionWhat were the interval and clinical importance of the severity difference?Required	The retained description concerns a small pilot with 74 participants and no significant severity difference. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Exact between-group effects, CIs, importance thresholds and required information	Material needed: Between-group effects/CIs and sample-size/importance plans. This records needed materials; no new research was executed.
26	Unverified	Full text not readStored summary read	N26 · Evidence conditionHow were multiple WHO, onset, mITT and PP comparisons planned?Required	WHO severity, onset and mITT/PP are mentioned together. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Planned analysis counts, hierarchy/adjustment and exploratory labels	Material needed: SAP, planned-comparison tables and analysis-specific results. This records needed materials; no new research was executed.
27	Partly verified	Full text not readStored summary read	N27 · Evidence conditionHow are the paper summary and citation related?Required	1 stored evidence entry and 1 citation point to the Shah et al. 2020 pilot RCT. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Family links among trial report, citation and registration	Material needed: Original paper, registration and reports from the same trial. This records needed materials; no new research was executed.
28	Partly verified	Full text not readStored summary read	N28 · Evidence conditionWhat is within scope and what remains unknown?Required	The original record limits application to the specified formulation, route, dose, duration, population, endpoint and comparator combination. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	The same mouthwash, cancer-treatment population, 6 weeks, active comparator and severity	Material needed: Additional studies of the exact same combination. This records needed materials; no new research was executed.
29	Partly verified	Full text not readStored summary read	N29 · Evidence conditionAre PMID, DOI, CTRI and actual reading distinguished?Required	The original citation lists Shah S et al., Indian J Dent Res. 2020;31:718-727, PMID 33433509, DOI 10.4103/ijdr.IJDR_822_18, CTRI/2018/04/013362. The material actually read is the stored summary. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Original citation and actual paper/registration reading status	Material needed: Original paper, registration and plans corresponding to the citation. This records needed materials; no new research was executed.
30	Partly verified	Full text not readStored summary read	N30 · Evidence conditionWhat do 2026-09-08 and the correction date mean?Required	The original record date is 2026-09-08; the English correction date is 2026-09-14. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Distinguishing the original record date, correction date and current authoring time	Material needed: Publication, receipt and reading records for actually provided new evidence. This records needed materials; no new research was executed.
31	Partly verified	Full text not readStored summary read	N31 · Evidence conditionHow should the English table and historical correction of 1 field be read?Required	The original English summary describes 74 participants, an onset delay of about 2 weeks and no significant severity difference. Generic descriptions remain in the English evidence table; the historical correction states that 1 field changed. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Roles of Korean/English evidence wording and the historical correction	Material needed: Complete before/after originals and specific English result tables. This records needed materials; no new research was executed.
32	Partly verified	Full text not readStored summary read	N32 · Evidence conditionHow does the original D/30 verdict differ from current material review?Required	The original D/30/Caution verdict is retained as historical information. Historical verification wording does not establish current external original-source reading or completed content review. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Roles of the original grade, score, caution label and historical verdict	Material needed: Original verdict and subsequently provided correction events. This records needed materials; no new research was executed.
33	Unverified	Full text not readStored summary read	N33 · Evidence conditionWhat were cash funding, prepared-product support and author interests?Required	The record describes academic research, with details of cash funding and prepared-product roles unverified. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Cash/product support, affiliations, conflicts of interest and reporting roles	Material needed: Funding/COI declarations, author affiliations and product-support descriptions. This records needed materials; no new research was executed.
34	Partly verified	Full text not readStored summary read	N34 · Evidence conditionWhich events and denominators underlie short-term tolerability?Required	The original safety wording describes similar short-term tolerability in a small trial. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Event definitions, collection, group events/denominators, discontinuation and missingness	Material needed: Group adverse-event/discontinuation and harm-collection tables. This records needed materials; no new research was executed.
35	Unverified	Full text not readStored summary read	N35 · Evidence conditionHow are harm timing, radiotherapy and concurrent exposures distinguished?Required	The original material describes topical rinsing during radiotherapy and 6-week short-term tolerability. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Onset, recovery, withdrawal/re-exposure, cancer treatment and other causes	Material needed: Individual-event timelines, concomitant medicines and original harm material. This records needed materials; no new research was executed.
36	Partly verified	Full text not readStored summary read	N36 · Evidence conditionWhat is known about safety beyond the short trial?Required	The record describes limited long-term safety, absorption and contamination-control material for freshly prepared nanoparticle mouthwash. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Long-term/rare harms, local/systemic absorption, preparation contamination and vulnerable groups	Material needed: Absorption/long-term follow-up, quality/contamination and vulnerable-population material. This records needed materials; no new research was executed.
37	Unverified	Full text not readStored summary read	N37 · Evidence conditionWere the same formulation, severity outcome or harms repeated elsewhere?Required	The stored record contains 1 trial summary and 1 citation. Other oral gels or general curcumin benefits are not treated as replication of this question. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Other teams/unique trials, formulation/endpoint matching, report families and harm events	Material needed: Additional original reports with the same formulation, population, comparison and endpoint. This records needed materials; no new research was executed.
38	Partly verified	Full text not readStored summary read	N38 · Evidence conditionHow are the summary actually read and unread original materials distinguished?Required	The stored summary is the material read. The original PubMed citation URL is linked; external materials remain unread and external access was not attempted. R01	Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.	Stored summary, external paper/registration/plans/quality/harms slots and update events	Material needed: Original or correction material provided or separately authorized by the user. This records needed materials; no new research was executed.

No items match your search or filter.

38 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-09-08
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: Material dates refer to the retained record date. They are not actual external reading or completed latest-search dates; authoring timestamps also remain distinct from completed content-review dates.
Population: The retained population is adults receiving head-and-neck radiotherapy. Cancer site/stage, age range, baseline oral condition, pre-existing mucositis and eligibility/exclusion criteria remain unverified; scope is not extended to other cancers or conditions.
Ingredient, formulation and route: The intervention is freshly prepared daily 0.1% mouthwash containing nanoparticle curcumin derived from Curcuma longa, used as an oral rinse and spit. Actual particle, additive, content, batch, preparation/storage and contamination-control material remains unverified; swallowed formulations and other oral gels remain distinct.
Dose: The retained concentration is 0.1% mouthwash. Volume and frequency are described only as following the trial protocol; exact amounts, frequency, contact time and adherence remain unverified. Daily or optimal doses are not calculated.
Comparator: The active comparator is 0.15% benzydamine mouthwash. Actual control use, common oral care, radiation dose, concurrent chemotherapy and rescue treatment remain unverified; the comparison is not relabeled as placebo or no treatment.
Measured outcome: The selected question concerns severe oral mucositis occurrence/severity by WHO criteria. Exact severity thresholds, visit assessments, group events/denominators, between-group effects/CIs and prespecified hierarchy remain unverified. The separate onset HR of approximately 0.5 and onset delay of about 2 weeks are not severe-mucositis prevention effects.
Duration: The record describes a 6-week comparison during radiotherapy. Rinse initiation, visits, censoring, discontinuation and post-treatment follow-up remain unverified; scope is not extended to long-term efficacy or overall safety.
Questions outside this scope: The original D/30/Caution and B/P/R1/I2/E0/B2/C0 are retained. Historical verdicts and cross-checking are historical records, not current external original-source verification, reassessment or independent clinical certification.; 74 is the randomized allocation total. Group allocation, mITT/PP analysis, completion, severity and harm denominators remain unverified; the allocation total is not reused for these denominators, and group sizes are not inferred.; The original narrative of no significant difference in the dichotomized severe outcome is retained. Exact group events, between-group effects, CIs and P values remain unverified; no significant difference does not establish equivalence, noninferiority or complete ineffectiveness.; An onset HR of approximately 0.5 and delay of about 2 weeks concern a separate onset outcome. Exact estimates, CIs, analysis counts, timing tables and calculation basis remain unverified; these are not reassigned to WHO-severity benefit or absolute risk reduction.; The retained descriptions of a triple-blind pilot RCT and mITT/PP do not establish verification of actual randomization, blinding, measurement, inclusion/exclusion, adherence or missing-data handling.; CTRI/2018/04/013362 in the citation and the unverified registration field are both retained. Original registration, protocol, SAP and prespecified endpoint/multiplicity plans remain unread; a listed identifier is not promoted to content verification.; The description of academic research and unverified cash-funding/prepared-product roles are retained. Similar short-term tolerability also does not substitute for verification of events, harm denominators, collection, causality, long-term absorption or contamination control.; The original record date 2026-09-08, correction of 1 English field on 2026-09-14 and stored-material authoring date 2026-10-06 remain distinct. Content-review dates are unrecorded; these dates and bibliographic links do not establish current latest searching or full-text reading.

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · 2020 · Report of a nanocurcumin mouthwash trial for radiation oral mucositis

PubMed

Material type: Stored summary of a triple-blind, active-controlled pilot RCT; details of mITT/PP, actual procedures and original result tables remain unverified
Materials actually read: Stored existing review summary read for preparation; external abstract/full text and registration unread, with external access not attempted
Findings recorded in the stored summary: Onset delayed with an HR of approximately 0.5; no significant difference in the dichotomized severe outcome
Record level: These are original narratives about selected WHO severity and a separate onset outcome. Exact severity effects, CIs and denominators remain unverified; the onset signal is not relabeled as prevention of severe mucositis.
Study overlap and independent replication: This record links a trial-report summary and original citation; material slots are not counted as independent trials. The 74 randomized participants remain distinct from unique-participant totals and endpoint analysis denominators; unique-trial counts, unique-participant totals and independent replication remain unverified.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored existing review summary	Existing stored summary acquired	Stored summary	Stored summary read	This is the stored summary actually read; it does not establish full-paper reading. This links the stored summary and original citation. External paper/registration identity, contents, report families and independent replication remain separately unverified; it does not establish current original-source reading. Material dates refer to the retained record date. They are not actual external reading or completed latest-search dates; authoring timestamps also remain distinct from completed content-review dates.
External paper identity link	Original bibliography link only; external content unread	Unread; no access attempt	Unread	The original PubMed citation URL is linked. External page contents, abstract and full text remain unread. This links the stored summary and original citation. External paper/registration identity, contents, report families and independent replication remain separately unverified; it does not establish current original-source reading. Material dates refer to the retained record date. They are not actual external reading or completed latest-search dates; authoring timestamps also remain distinct from completed content-review dates.
External full paper	Original bibliography link only; external content unread	Unread; no access attempt	Unread	This is the original paper bibliographic link; it does not establish full-text acquisition, download or reading. This links the stored summary and original citation. External paper/registration identity, contents, report families and independent replication remain separately unverified; it does not establish current original-source reading. Material dates refer to the retained record date. They are not actual external reading or completed latest-search dates; authoring timestamps also remain distinct from completed content-review dates.
Registration material	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	CTRI/2018/04/013362 appears in the original citation, but the registration URL, contents and plan history remain unverified. This links the stored summary and original citation. External paper/registration identity, contents, report families and independent replication remain separately unverified; it does not establish current original-source reading. Material dates refer to the retained record date. They are not actual external reading or completed latest-search dates; authoring timestamps also remain distinct from completed content-review dates.
Protocol and analysis plan	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Protocol, SAP and prespecified endpoint/analysis plans remain unread; existence and public availability of separate materials also remain unverified. This links the stored summary and original citation. External paper/registration identity, contents, report families and independent replication remain separately unverified; it does not establish current original-source reading. Material dates refer to the retained record date. They are not actual external reading or completed latest-search dates; authoring timestamps also remain distinct from completed content-review dates.
Group flow, analysis and result tables	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	74 is the allocation denominator; group flow, mITT/PP, WHO/onset result tables and actual analysis denominators remain unverified. This links the stored summary and original citation. External paper/registration identity, contents, report families and independent replication remain separately unverified; it does not establish current original-source reading. Material dates refer to the retained record date. They are not actual external reading or completed latest-search dates; authoring timestamps also remain distinct from completed content-review dates.
Mouthwash formulation, preparation and use material	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	The descriptions of 0.1% concentration and fresh preparation are retained. Composition, actual volume/frequency, quality and public availability/acquisition of additional documents remain unverified. This links the stored summary and original citation. External paper/registration identity, contents, report families and independent replication remain separately unverified; it does not establish current original-source reading. Material dates refer to the retained record date. They are not actual external reading or completed latest-search dates; authoring timestamps also remain distinct from completed content-review dates.
Harm, absorption, long-term and quality material	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	Short-term tolerability wording is not relabeled as absence of events or overall safety. Harm counts, absorption, long-term follow-up and contamination-control material remain unread. This links the stored summary and original citation. External paper/registration identity, contents, report families and independent replication remain separately unverified; it does not establish current original-source reading. Material dates refer to the retained record date. They are not actual external reading or completed latest-search dates; authoring timestamps also remain distinct from completed content-review dates.
Funding, product-support and conflict-of-interest material	Needed material; existence and public availability unverified	Unread; no access attempt	Unread	The academic-setting description and unverified cash/prepared-product roles are retained; original support and conflict-of-interest disclosures remain unread. This links the stored summary and original citation. External paper/registration identity, contents, report families and independent replication remain separately unverified; it does not establish current original-source reading. Material dates refer to the retained record date. They are not actual external reading or completed latest-search dates; authoring timestamps also remain distinct from completed content-review dates.

Report counts versus independent study counts

This record links a trial-report summary and original citation; material slots are not counted as independent trials. The 74 randomized participants remain distinct from unique-participant totals and endpoint analysis denominators; unique-trial counts, unique-participant totals and independent replication remain unverified.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Which mouthwash and mucositis question is presented?

Required materials and conditions: Intervention, population, severity, time, active comparator and original claim
Conditions for verification: Original records on Intervention, population, severity, time, active comparator and original claim must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Intervention, population, severity, time, active comparator and original claim is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N02 · What is the 0.1% nanocurcumin mouthwash?

Required materials and conditions: Curcuma longa-derived curcumin nanoparticles and freshly prepared 0.1% mouthwash
Conditions for verification: Original records on Curcuma longa-derived curcumin nanoparticles and freshly prepared 0.1% mouthwash must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Curcuma longa-derived curcumin nanoparticles and freshly prepared 0.1% mouthwash is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N03 · Are rinse-and-spit use and other oral products distinguished?

Required materials and conditions: The topical oral rinse-and-spit route
Conditions for verification: Original records on The topical oral rinse-and-spit route must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on The topical oral rinse-and-spit route is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N04 · Which radiotherapy population is included?

Required materials and conditions: Eligibility and baseline conditions of adults receiving head-and-neck radiotherapy
Conditions for verification: Original records on Eligibility and baseline conditions of adults receiving head-and-neck radiotherapy must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Eligibility and baseline conditions of adults receiving head-and-neck radiotherapy is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N05 · What were the radiation dose, chemotherapy and oral-care differences?

Required materials and conditions: Radiotherapy schedules/cumulative doses, concurrent anticancer treatment and basic oral care
Conditions for verification: Original records on Radiotherapy schedules/cumulative doses, concurrent anticancer treatment and basic oral care must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Radiotherapy schedules/cumulative doses, concurrent anticancer treatment and basic oral care is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N06 · What was compared with benzydamine?

Required materials and conditions: Actual use of 0.15% benzydamine mouthwash
Conditions for verification: Original records on Actual use of 0.15% benzydamine mouthwash must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Actual use of 0.15% benzydamine mouthwash is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N07 · What were the actual volume and frequency for the 0.1% rinse?

Required materials and conditions: Concentration, volume per 1 rinse, daily frequency and exposure time
Conditions for verification: Original records on Concentration, volume per 1 rinse, daily frequency and exposure time must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Concentration, volume per 1 rinse, daily frequency and exposure time is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N08 · How was quality maintained for freshly prepared daily mouthwash?

Required materials and conditions: Preparation, storage, expiry, contamination control and quality tracking
Conditions for verification: Original records on Preparation, storage, expiry, contamination control and quality tracking must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Preparation, storage, expiry, contamination control and quality tracking is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N09 · When during the 6 weeks were treatment and assessments performed?

Required materials and conditions: Initiation, radiotherapy schedules, visit assessments and completion/discontinuation
Conditions for verification: Original records on Initiation, radiotherapy schedules, visit assessments and completion/discontinuation must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Initiation, radiotherapy schedules, visit assessments and completion/discontinuation is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N10 · Are WHO severity and mucositis onset the same outcome?

Required materials and conditions: Distinguishing WHO severity/occurrence from time to onset
Conditions for verification: Original records on Distinguishing WHO severity/occurrence from time to onset must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Distinguishing WHO severity/occurrence from time to onset is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N11 · Which WHO grades were dichotomized as severe?

Required materials and conditions: WHO grades, severity cutoff, assessors and repeated measurement
Conditions for verification: Original records on WHO grades, severity cutoff, assessors and repeated measurement must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on WHO grades, severity cutoff, assessors and repeated measurement is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N12 · Which endpoint was prespecified as primary (1st)?

Required materials and conditions: Registration, protocol, SAP and endpoint/analysis hierarchy
Conditions for verification: Original records on Registration, protocol, SAP and endpoint/analysis hierarchy must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Registration, protocol, SAP and endpoint/analysis hierarchy is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N13 · What denominator does 74 represent?

Required materials and conditions: Distinguishing randomized, group-allocation, analysis and completion denominators
Conditions for verification: Original records on Distinguishing randomized, group-allocation, analysis and completion denominators must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Distinguishing randomized, group-allocation, analysis and completion denominators is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N14 · Who was included in mITT and what did it estimate?

Required materials and conditions: mITT inclusion conditions, exclusions, group counts and target effects
Conditions for verification: Original records on mITT inclusion conditions, exclusions, group counts and target effects must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on mITT inclusion conditions, exclusions, group counts and target effects is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N15 · How did PP results and denominators differ from mITT?

Required materials and conditions: PP adherence criteria, denominators and severity/onset results
Conditions for verification: Original records on PP adherence criteria, denominators and severity/onset results must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on PP adherence criteria, denominators and severity/onset results is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N16 · What was the between-group result for severe-mucositis prevention?

Required materials and conditions: Severe events/denominators, between-group effects, CIs and timepoints
Conditions for verification: Original records on Severe events/denominators, between-group effects, CIs and timepoints must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Severe events/denominators, between-group effects, CIs and timepoints is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N17 · What do the onset HR of approximately 0.5 and delay of about 2 weeks mean?

Required materials and conditions: Definitions, units, denominators and CIs for time-to-onset results
Conditions for verification: Original records on Definitions, units, denominators and CIs for time-to-onset results must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Definitions, units, denominators and CIs for time-to-onset results is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N18 · How were onset assessment intervals, censoring and follow-up handled?

Required materials and conditions: Assessment intervals, censoring, event times and radiotherapy exposure
Conditions for verification: Original records on Assessment intervals, censoring, event times and radiotherapy exposure must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Assessment intervals, censoring, event times and radiotherapy exposure is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N19 · Does no significant difference establish equivalence?

Required materials and conditions: Superiority/noninferiority/equivalence designs, margins and CIs
Conditions for verification: Original records on Superiority/noninferiority/equivalence designs, margins and CIs must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Superiority/noninferiority/equivalence designs, margins and CIs is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N20 · How were random sequences and allocation concealment implemented?

Required materials and conditions: Sequence generation, allocation concealment and baseline balance
Conditions for verification: Original records on Sequence generation, allocation concealment and baseline balance must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Sequence generation, allocation concealment and baseline balance is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N21 · What did triple blinding and blinded WHO assessment cover?

Required materials and conditions: Participant, provider and assessor blinding, and distinguishability of the rinses
Conditions for verification: Original records on Participant, provider and assessor blinding, and distinguishability of the rinses must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Participant, provider and assessor blinding, and distinguishability of the rinses is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N22 · What were rinse adherence and treatment deviations?

Required materials and conditions: Use diaries, nonuse, crossover, radiotherapy interruption and rescue treatment
Conditions for verification: Original records on Use diaries, nonuse, crossover, radiotherapy interruption and rescue treatment must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Use diaries, nonuse, crossover, radiotherapy interruption and rescue treatment is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N23 · Which participants had missing outcome data?

Required materials and conditions: Group missingness/attrition, reasons, handling and sensitivity analyses
Conditions for verification: Original records on Group missingness/attrition, reasons, handling and sensitivity analyses must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Group missingness/attrition, reasons, handling and sensitivity analyses is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N24 · How did registration plans correspond to reported results?

Required materials and conditions: CTRI, protocol, SAP and all planned endpoints/analyses
Conditions for verification: Original records on CTRI, protocol, SAP and all planned endpoints/analyses must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on CTRI, protocol, SAP and all planned endpoints/analyses is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N25 · What were the interval and clinical importance of the severity difference?

Required materials and conditions: Exact between-group effects, CIs, importance thresholds and required information
Conditions for verification: Original records on Exact between-group effects, CIs, importance thresholds and required information must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Exact between-group effects, CIs, importance thresholds and required information is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N26 · How were multiple WHO, onset, mITT and PP comparisons planned?

Required materials and conditions: Planned analysis counts, hierarchy/adjustment and exploratory labels
Conditions for verification: Original records on Planned analysis counts, hierarchy/adjustment and exploratory labels must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Planned analysis counts, hierarchy/adjustment and exploratory labels is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N27 · How are the paper summary and citation related?

Required materials and conditions: Family links among trial report, citation and registration
Conditions for verification: Original records on Family links among trial report, citation and registration must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Family links among trial report, citation and registration is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N28 · What is within scope and what remains unknown?

Required materials and conditions: The same mouthwash, cancer-treatment population, 6 weeks, active comparator and severity
Conditions for verification: Original records on The same mouthwash, cancer-treatment population, 6 weeks, active comparator and severity must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on The same mouthwash, cancer-treatment population, 6 weeks, active comparator and severity is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N29 · Are PMID, DOI, CTRI and actual reading distinguished?

Required materials and conditions: Original citation and actual paper/registration reading status
Conditions for verification: Original records on Original citation and actual paper/registration reading status must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Original citation and actual paper/registration reading status is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N30 · What do 2026-09-08 and the correction date mean?

Required materials and conditions: Distinguishing the original record date, correction date and current authoring time
Conditions for verification: Original records on Distinguishing the original record date, correction date and current authoring time must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Distinguishing the original record date, correction date and current authoring time is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N31 · How should the English table and historical correction of 1 field be read?

Required materials and conditions: Roles of Korean/English evidence wording and the historical correction
Conditions for verification: Original records on Roles of Korean/English evidence wording and the historical correction must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Roles of Korean/English evidence wording and the historical correction is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N32 · How does the original D/30 verdict differ from current material review?

Required materials and conditions: Roles of the original grade, score, caution label and historical verdict
Conditions for verification: Original records on Roles of the original grade, score, caution label and historical verdict must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Roles of the original grade, score, caution label and historical verdict is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N33 · What were cash funding, prepared-product support and author interests?

Required materials and conditions: Cash/product support, affiliations, conflicts of interest and reporting roles
Conditions for verification: Original records on Cash/product support, affiliations, conflicts of interest and reporting roles must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Cash/product support, affiliations, conflicts of interest and reporting roles is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N34 · Which events and denominators underlie short-term tolerability?

Required materials and conditions: Event definitions, collection, group events/denominators, discontinuation and missingness
Conditions for verification: Original records on Event definitions, collection, group events/denominators, discontinuation and missingness must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Event definitions, collection, group events/denominators, discontinuation and missingness is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N35 · How are harm timing, radiotherapy and concurrent exposures distinguished?

Required materials and conditions: Onset, recovery, withdrawal/re-exposure, cancer treatment and other causes
Conditions for verification: Original records on Onset, recovery, withdrawal/re-exposure, cancer treatment and other causes must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Onset, recovery, withdrawal/re-exposure, cancer treatment and other causes is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N36 · What is known about safety beyond the short trial?

Required materials and conditions: Long-term/rare harms, local/systemic absorption, preparation contamination and vulnerable groups
Conditions for verification: Original records on Long-term/rare harms, local/systemic absorption, preparation contamination and vulnerable groups must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Long-term/rare harms, local/systemic absorption, preparation contamination and vulnerable groups is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N37 · Were the same formulation, severity outcome or harms repeated elsewhere?

Required materials and conditions: Other teams/unique trials, formulation/endpoint matching, report families and harm events
Conditions for verification: Original records on Other teams/unique trials, formulation/endpoint matching, report families and harm events must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Other teams/unique trials, formulation/endpoint matching, report families and harm events is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

N38 · How are the summary actually read and unread original materials distinguished?

Required materials and conditions: Stored summary, external paper/registration/plans/quality/harms slots and update events
Conditions for verification: Original records on Stored summary, external paper/registration/plans/quality/harms slots and update events must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Requirement and applicability: Required
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Why this condition is needed: Material on Stored summary, external paper/registration/plans/quality/harms slots and update events is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed.

What the statuses mean

Partly verified: Partial information from the stored summary is linked; detailed originals and content review remain incomplete.
Unverified: Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety.
Review incomplete: Review of existing content remains incomplete.
Met: This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work.
Not reported: Unreported within material actually read. Unread external material is not relabeled as unreported.
Inaccessible: This means actual access failure. External access was not attempted in this work, so this state was not assigned.
Not applicable: Used only with an application exception and reason based on the question scope.
Conflicting data: This requires actual comparison of materials; no new conflict judgment was made in this work.
Insufficient evidence for the conditions: This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade.

Change history

2026-10-24 · Public page/material version 1.0

The public view and materials were prepared from the existing 38 items. No new clinical search, verification-state change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-09-08) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Which mouthwash and mucositis question is presented?

Current findings: The original question concerns prevention of oral-mucositis severity during head-and-neck radiotherapy. Onset results from the same trial remain separate supportive information.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Review of the independent claim boundary remains unrecorded.
Required materials and conditions: Intervention, population, severity, time, active comparator and original claim
Materials to obtain first: Original-trial question, eligibility and endpoint plans
Further research: Material needed: Original-trial question, eligibility and endpoint plans. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Intervention, population, severity, time, active comparator and original claim must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Intervention, population, severity, time, active comparator and original claim is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N02 · What is the 0.1% nanocurcumin mouthwash?

Current findings: The record describes freshly prepared daily 0.1% mouthwash.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Particle size, content analyses, additives and actual batch quality remain unverified.
Required materials and conditions: Curcuma longa-derived curcumin nanoparticles and freshly prepared 0.1% mouthwash
Materials to obtain first: Formulation composition, nanoparticle characteristics, batch analyses and preparation procedures
Further research: Material needed: Formulation composition, nanoparticle characteristics, batch analyses and preparation procedures. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Curcuma longa-derived curcumin nanoparticles and freshly prepared 0.1% mouthwash must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Curcuma longa-derived curcumin nanoparticles and freshly prepared 0.1% mouthwash is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N03 · Are rinse-and-spit use and other oral products distinguished?

Current findings: The route is topical oral rinsing followed by spitting. The original record warns against treating swallowed formulations and topical products as interchangeable.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Actual contact time, swallowed amounts and direct comparisons with gels remain unverified.
Required materials and conditions: The topical oral rinse-and-spit route
Materials to obtain first: Rinse-use procedures and exposure records
Further research: Material needed: Rinse-use procedures and exposure records. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on The topical oral rinse-and-spit route must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on The topical oral rinse-and-spit route is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N04 · Which radiotherapy population is included?

Current findings: The retained population is adults receiving head-and-neck radiotherapy.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Age range, cancer site/stage, baseline mucositis, oral condition and exclusion criteria remain unverified.
Required materials and conditions: Eligibility and baseline conditions of adults receiving head-and-neck radiotherapy
Materials to obtain first: Eligibility, baseline-characteristic and radiotherapy-population tables
Further research: Material needed: Eligibility, baseline-characteristic and radiotherapy-population tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Eligibility and baseline conditions of adults receiving head-and-neck radiotherapy must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Eligibility and baseline conditions of adults receiving head-and-neck radiotherapy is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N05 · What were the radiation dose, chemotherapy and oral-care differences?

Current findings: The original material limits the comparison to treatment during radiotherapy.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Group radiation doses, concurrent chemotherapy, oral hygiene, analgesia and rescue treatment remain unverified.
Required materials and conditions: Radiotherapy schedules/cumulative doses, concurrent anticancer treatment and basic oral care
Materials to obtain first: Group cancer-treatment, oral-care and rescue-medication tables
Further research: Material needed: Group cancer-treatment, oral-care and rescue-medication tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Radiotherapy schedules/cumulative doses, concurrent anticancer treatment and basic oral care must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Radiotherapy schedules/cumulative doses, concurrent anticancer treatment and basic oral care is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N06 · What was compared with benzydamine?

Current findings: The retained direct comparison is 0.1% nanocurcumin versus 0.15% benzydamine for 6 weeks.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Control volume, frequency, contact time and common care remain unverified.
Required materials and conditions: Actual use of 0.15% benzydamine mouthwash
Materials to obtain first: Control-use procedures and care common to both groups
Further research: Material needed: Control-use procedures and care common to both groups. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Actual use of 0.15% benzydamine mouthwash must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Actual use of 0.15% benzydamine mouthwash is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N07 · What were the actual volume and frequency for the 0.1% rinse?

Current findings: The record describes 0.1% mouthwash, with volume and frequency following the original trial procedures.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Exact mL per use, uses per day, contact time and total dose remain unverified.
Required materials and conditions: Concentration, volume per 1 rinse, daily frequency and exposure time
Materials to obtain first: Trial rinse procedures and use diaries
Further research: Material needed: Trial rinse procedures and use diaries. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Concentration, volume per 1 rinse, daily frequency and exposure time must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Concentration, volume per 1 rinse, daily frequency and exposure time is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N08 · How was quality maintained for freshly prepared daily mouthwash?

Current findings: The record describes freshly prepared daily nanoparticle mouthwash and limited contamination-control material.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Preparers, sterility/microbiology, storage, stability and test results remain unverified.
Required materials and conditions: Preparation, storage, expiry, contamination control and quality tracking
Materials to obtain first: Preparation SOPs, stability and microbial/quality records
Further research: Material needed: Preparation SOPs, stability and microbial/quality records. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Preparation, storage, expiry, contamination control and quality tracking must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Preparation, storage, expiry, contamination control and quality tracking is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N09 · When during the 6 weeks were treatment and assessments performed?

Current findings: The retained duration is 6 weeks during radiotherapy.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Rinse initiation, visit schedules, treatment discontinuation and follow-up beyond 6 weeks remain unverified.
Required materials and conditions: Initiation, radiotherapy schedules, visit assessments and completion/discontinuation
Materials to obtain first: Trial visit/treatment schedules and follow-up plans
Further research: Material needed: Trial visit/treatment schedules and follow-up plans. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Initiation, radiotherapy schedules, visit assessments and completion/discontinuation must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Initiation, radiotherapy schedules, visit assessments and completion/discontinuation is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N10 · Are WHO severity and mucositis onset the same outcome?

Current findings: WHO oral-mucositis occurrence/severity is the selected question; delayed onset is described as a separate supportive result.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Exact definitions, timepoints and analysis tables for each endpoint remain unverified.
Required materials and conditions: Distinguishing WHO severity/occurrence from time to onset
Materials to obtain first: Endpoint definitions, analysis plans and result tables
Further research: Material needed: Endpoint definitions, analysis plans and result tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Distinguishing WHO severity/occurrence from time to onset must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Distinguishing WHO severity/occurrence from time to onset is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N11 · Which WHO grades were dichotomized as severe?

Current findings: Severe oral-mucositis occurrence/severity by WHO criteria and a dichotomized severe-outcome comparison are mentioned.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: WHO cutoffs, assessment manuals, visit grades and assessment agreement remain unverified.
Required materials and conditions: WHO grades, severity cutoff, assessors and repeated measurement
Materials to obtain first: WHO grading criteria, assessor guidance and visit tables
Further research: Material needed: WHO grading criteria, assessor guidance and visit tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on WHO grades, severity cutoff, assessors and repeated measurement must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on WHO grades, severity cutoff, assessors and repeated measurement is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N12 · Which endpoint was prespecified as primary (1st)?

Current findings: The retained record labels the WHO-severity endpoint as primary.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: The trial prespecified primary (1st) hierarchy and amendments remain unverified because original registration/plans are unread.
Required materials and conditions: Registration, protocol, SAP and endpoint/analysis hierarchy
Materials to obtain first: Original CTRI registration, dated plans and SAP
Further research: Material needed: Original CTRI registration, dated plans and SAP. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Registration, protocol, SAP and endpoint/analysis hierarchy must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Registration, protocol, SAP and endpoint/analysis hierarchy is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N13 · What denominator does 74 represent?

Current findings: The retained evidence describes 74 randomized participants.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Group allocation counts, mITT/PP analysis counts, completion counts and endpoint denominators remain unverified.
Required materials and conditions: Distinguishing randomized, group-allocation, analysis and completion denominators
Materials to obtain first: CONSORT flow and group-allocation/analysis tables
Further research: Material needed: CONSORT flow and group-allocation/analysis tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Distinguishing randomized, group-allocation, analysis and completion denominators must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Distinguishing randomized, group-allocation, analysis and completion denominators is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N14 · Who was included in mITT and what did it estimate?

Current findings: The design mentions mITT and PP; the retained explanation describes an mITT onset HR signal.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: mITT definitions, exclusion reasons, group denominators and links to severity analyses remain unverified.
Required materials and conditions: mITT inclusion conditions, exclusions, group counts and target effects
Materials to obtain first: mITT definitions, flow and endpoint-specific result tables
Further research: Material needed: mITT definitions, flow and endpoint-specific result tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on mITT inclusion conditions, exclusions, group counts and target effects must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on mITT inclusion conditions, exclusions, group counts and target effects is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N15 · How did PP results and denominators differ from mITT?

Current findings: Only the description that the trial included PP remains in the record.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: PP group counts, adherence conditions, effect estimates and differences from mITT remain unverified.
Required materials and conditions: PP adherence criteria, denominators and severity/onset results
Materials to obtain first: PP definitions, analysis and attrition tables
Further research: Material needed: PP definitions, analysis and attrition tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on PP adherence criteria, denominators and severity/onset results must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on PP adherence criteria, denominators and severity/onset results is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N16 · What was the between-group result for severe-mucositis prevention?

Current findings: The original narrative describes no significant difference in the dichotomized severe outcome and no evidence of better severity prevention than benzydamine.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Group event counts, exact effects/RRs/differences, CIs, P values and analysis timepoints remain unverified.
Required materials and conditions: Severe events/denominators, between-group effects, CIs and timepoints
Materials to obtain first: WHO-severity result tables and analysis output
Further research: Material needed: WHO-severity result tables and analysis output. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Severe events/denominators, between-group effects, CIs and timepoints must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Severe events/denominators, between-group effects, CIs and timepoints is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N17 · What do the onset HR of approximately 0.5 and delay of about 2 weeks mean?

Current findings: The retained result describes delayed onset with an HR of approximately 0.5; the original summary describes onset about 2 weeks later. The mITT onset signal remains distinct from WHO severity.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Exact HRs, CIs, analysis counts, event counts, median onset times and the calculation basis for the 2-week delay remain unverified.
Required materials and conditions: Definitions, units, denominators and CIs for time-to-onset results
Materials to obtain first: Onset curves, hazard analyses and timing tables
Further research: Material needed: Onset curves, hazard analyses and timing tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Definitions, units, denominators and CIs for time-to-onset results must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Definitions, units, denominators and CIs for time-to-onset results is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N18 · How were onset assessment intervals, censoring and follow-up handled?

Current findings: The original material describes a 6-week duration and an onset HR signal.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Visit intervals, censoring rules, event counts, follow-up losses and proportional-hazards assumptions remain unverified.
Required materials and conditions: Assessment intervals, censoring, event times and radiotherapy exposure
Materials to obtain first: Onset statistical methods and individual timing/follow-up material
Further research: Material needed: Onset statistical methods and individual timing/follow-up material. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Assessment intervals, censoring, event times and radiotherapy exposure must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Assessment intervals, censoring, event times and radiotherapy exposure is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N19 · Does no significant difference establish equivalence?

Current findings: The original record says superiority and equivalence were not established and complete ineffectiveness cannot be concluded.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Equivalence/noninferiority margins, testing designs and relevant CIs remain unverified.
Required materials and conditions: Superiority/noninferiority/equivalence designs, margins and CIs
Materials to obtain first: Trial hypotheses, margins and effect intervals
Further research: Material needed: Trial hypotheses, margins and effect intervals. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Superiority/noninferiority/equivalence designs, margins and CIs must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Superiority/noninferiority/equivalence designs, margins and CIs is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N20 · How were random sequences and allocation concealment implemented?

Current findings: The retained descriptions identify a pilot RCT and 74 randomized participants.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Sequence generation, allocation ratio, concealment and baseline balance remain unverified.
Required materials and conditions: Sequence generation, allocation concealment and baseline balance
Materials to obtain first: Randomization procedures and baseline tables
Further research: Material needed: Randomization procedures and baseline tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Sequence generation, allocation concealment and baseline balance must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Sequence generation, allocation concealment and baseline balance is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N21 · What did triple blinding and blinded WHO assessment cover?

Current findings: The study title and design describe a triple-blind pilot RCT.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Blinded roles, color/taste, maintenance of blinding, WHO assessors and measurement reliability remain unverified.
Required materials and conditions: Participant, provider and assessor blinding, and distinguishability of the rinses
Materials to obtain first: Blinding procedures, product appearance and assessor guidance
Further research: Material needed: Blinding procedures, product appearance and assessor guidance. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Participant, provider and assessor blinding, and distinguishability of the rinses must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Participant, provider and assessor blinding, and distinguishability of the rinses is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N22 · What were rinse adherence and treatment deviations?

Current findings: The retained record describes a 6-week rinse comparison and mITT/PP analyses.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Adherence, discontinuation/crossover, rescue treatment and handling of deviations remain unverified.
Required materials and conditions: Use diaries, nonuse, crossover, radiotherapy interruption and rescue treatment
Materials to obtain first: Use diaries, discontinuation reasons and analysis plans
Further research: Material needed: Use diaries, discontinuation reasons and analysis plans. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Use diaries, nonuse, crossover, radiotherapy interruption and rescue treatment must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Use diaries, nonuse, crossover, radiotherapy interruption and rescue treatment is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N23 · Which participants had missing outcome data?

Current findings: The original record describes 74 randomized participants and an mITT/PP design.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Endpoint missingness, group attrition, reasons and imputation/sensitivity analyses remain unverified.
Required materials and conditions: Group missingness/attrition, reasons, handling and sensitivity analyses
Materials to obtain first: Group flow, missing-data handling and sensitivity tables
Further research: Material needed: Group flow, missing-data handling and sensitivity tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Group missingness/attrition, reasons, handling and sensitivity analyses must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Group missingness/attrition, reasons, handling and sensitivity analyses is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N24 · How did registration plans correspond to reported results?

Current findings: The citation lists CTRI/2018/04/013362, while the original trial-registration field says unverified.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Correspondence remains unverified because original registration, plan versions and result tables are unread.
Required materials and conditions: CTRI, protocol, SAP and all planned endpoints/analyses
Materials to obtain first: Registration history, protocol, SAP and complete endpoint tables
Further research: Material needed: Registration history, protocol, SAP and complete endpoint tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on CTRI, protocol, SAP and all planned endpoints/analyses must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on CTRI, protocol, SAP and all planned endpoints/analyses is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N25 · What were the interval and clinical importance of the severity difference?

Current findings: The retained description concerns a small pilot with 74 participants and no significant severity difference.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Effect CIs, prespecified important differences, design sample-size rationale and exact P values remain unverified.
Required materials and conditions: Exact between-group effects, CIs, importance thresholds and required information
Materials to obtain first: Between-group effects/CIs and sample-size/importance plans
Further research: Material needed: Between-group effects/CIs and sample-size/importance plans. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Exact between-group effects, CIs, importance thresholds and required information must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Exact between-group effects, CIs, importance thresholds and required information is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N26 · How were multiple WHO, onset, mITT and PP comparisons planned?

Current findings: WHO severity, onset and mITT/PP are mentioned together.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Prespecified comparison lists, multiplicity handling and exploratory/confirmatory distinctions remain unverified.
Required materials and conditions: Planned analysis counts, hierarchy/adjustment and exploratory labels
Materials to obtain first: SAP, planned-comparison tables and analysis-specific results
Further research: Material needed: SAP, planned-comparison tables and analysis-specific results. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Planned analysis counts, hierarchy/adjustment and exploratory labels must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Planned analysis counts, hierarchy/adjustment and exploratory labels is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N27 · How are the paper summary and citation related?

Current findings: 1 stored evidence entry and 1 citation point to the Shah et al. 2020 pilot RCT.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: External identity, registration/paper family links and unique-trial/participant totals remain unverified.
Required materials and conditions: Family links among trial report, citation and registration
Materials to obtain first: Original paper, registration and reports from the same trial
Further research: Material needed: Original paper, registration and reports from the same trial. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Family links among trial report, citation and registration must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Family links among trial report, citation and registration is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N28 · What is within scope and what remains unknown?

Current findings: The original record limits application to the specified formulation, route, dose, duration, population, endpoint and comparator combination.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Direct effects of other mouthwashes, gels, swallowed curcumin, other conditions and periods beyond 6 weeks remain unverified.
Required materials and conditions: The same mouthwash, cancer-treatment population, 6 weeks, active comparator and severity
Materials to obtain first: Additional studies of the exact same combination
Further research: Material needed: Additional studies of the exact same combination. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on The same mouthwash, cancer-treatment population, 6 weeks, active comparator and severity must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on The same mouthwash, cancer-treatment population, 6 weeks, active comparator and severity is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N29 · Are PMID, DOI, CTRI and actual reading distinguished?

Current findings: The original citation lists Shah S et al., Indian J Dent Res. 2020;31:718-727, PMID 33433509, DOI 10.4103/ijdr.IJDR_822_18, CTRI/2018/04/013362. The material actually read is the stored summary.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: External abstract/full text, CTRI and protocol remain unread; external access was not attempted.
Required materials and conditions: Original citation and actual paper/registration reading status
Materials to obtain first: Original paper, registration and plans corresponding to the citation
Further research: Material needed: Original paper, registration and plans corresponding to the citation. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Original citation and actual paper/registration reading status must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Original citation and actual paper/registration reading status is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N30 · What do 2026-09-08 and the correction date mean?

Current findings: The original record date is 2026-09-08; the English correction date is 2026-09-14.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: No explicit evidence-search cutoff or current external-reading date is recorded.
Required materials and conditions: Distinguishing the original record date, correction date and current authoring time
Materials to obtain first: Publication, receipt and reading records for actually provided new evidence
Further research: Material needed: Publication, receipt and reading records for actually provided new evidence. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Distinguishing the original record date, correction date and current authoring time must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Distinguishing the original record date, correction date and current authoring time is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N31 · How should the English table and historical correction of 1 field be read?

Current findings: The original English summary describes 74 participants, an onset delay of about 2 weeks and no significant severity difference. Generic descriptions remain in the English evidence table; the historical correction states that 1 field changed.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Original before/after wording identifying the changed field and detailed English-content review remain unrecorded.
Required materials and conditions: Roles of Korean/English evidence wording and the historical correction
Materials to obtain first: Complete before/after originals and specific English result tables
Further research: Material needed: Complete before/after originals and specific English result tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Roles of Korean/English evidence wording and the historical correction must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Roles of Korean/English evidence wording and the historical correction is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N32 · How does the original D/30 verdict differ from current material review?

Current findings: The original D/30/Caution verdict is retained as historical information. Historical verification wording does not establish current external original-source reading or completed content review.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Completed current content review or external clinical validation is not recorded.
Required materials and conditions: Roles of the original grade, score, caution label and historical verdict
Materials to obtain first: Original verdict and subsequently provided correction events
Further research: Material needed: Original verdict and subsequently provided correction events. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Roles of the original grade, score, caution label and historical verdict must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Roles of the original grade, score, caution label and historical verdict is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N33 · What were cash funding, prepared-product support and author interests?

Current findings: The record describes academic research, with details of cash funding and prepared-product roles unverified.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Amounts, prepared-product support, employee authorship and original conflict-of-interest declarations remain unverified.
Required materials and conditions: Cash/product support, affiliations, conflicts of interest and reporting roles
Materials to obtain first: Funding/COI declarations, author affiliations and product-support descriptions
Further research: Material needed: Funding/COI declarations, author affiliations and product-support descriptions. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Cash/product support, affiliations, conflicts of interest and reporting roles must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Cash/product support, affiliations, conflicts of interest and reporting roles is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N34 · Which events and denominators underlie short-term tolerability?

Current findings: The original safety wording describes similar short-term tolerability in a small trial.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Event types, group event/person counts, harm denominators, collection methods and attrition remain unverified.
Required materials and conditions: Event definitions, collection, group events/denominators, discontinuation and missingness
Materials to obtain first: Group adverse-event/discontinuation and harm-collection tables
Further research: Material needed: Group adverse-event/discontinuation and harm-collection tables. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Event definitions, collection, group events/denominators, discontinuation and missingness must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Event definitions, collection, group events/denominators, discontinuation and missingness is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N35 · How are harm timing, radiotherapy and concurrent exposures distinguished?

Current findings: The original material describes topical rinsing during radiotherapy and 6-week short-term tolerability.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Individual-event timing, improvement after withdrawal/re-exposure, concomitant medicines and underlying-condition alternatives remain unverified.
Required materials and conditions: Onset, recovery, withdrawal/re-exposure, cancer treatment and other causes
Materials to obtain first: Individual-event timelines, concomitant medicines and original harm material
Further research: Material needed: Individual-event timelines, concomitant medicines and original harm material. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Onset, recovery, withdrawal/re-exposure, cancer treatment and other causes must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Onset, recovery, withdrawal/re-exposure, cancer treatment and other causes is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N36 · What is known about safety beyond the short trial?

Current findings: The record describes limited long-term safety, absorption and contamination-control material for freshly prepared nanoparticle mouthwash.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Long-term exposure, absorbed amounts, rare events, vulnerable populations and preparation-quality harm material remain unverified.
Required materials and conditions: Long-term/rare harms, local/systemic absorption, preparation contamination and vulnerable groups
Materials to obtain first: Absorption/long-term follow-up, quality/contamination and vulnerable-population material
Further research: Material needed: Absorption/long-term follow-up, quality/contamination and vulnerable-population material. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Long-term/rare harms, local/systemic absorption, preparation contamination and vulnerable groups must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Long-term/rare harms, local/systemic absorption, preparation contamination and vulnerable groups is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N37 · Were the same formulation, severity outcome or harms repeated elsewhere?

Current findings: The stored record contains 1 trial summary and 1 citation. Other oral gels or general curcumin benefits are not treated as replication of this question.
Verification status: Unverified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Independent replication of severity findings for the same rinse, independent harm cases and unique-trial counts remain unverified.
Required materials and conditions: Other teams/unique trials, formulation/endpoint matching, report families and harm events
Materials to obtain first: Additional original reports with the same formulation, population, comparison and endpoint
Further research: Material needed: Additional original reports with the same formulation, population, comparison and endpoint. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Other teams/unique trials, formulation/endpoint matching, report families and harm events must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Other teams/unique trials, formulation/endpoint matching, report families and harm events is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01

N38 · How are the summary actually read and unread original materials distinguished?

Current findings: The stored summary is the material read. The original PubMed citation URL is linked; external materials remain unread and external access was not attempted.
Verification status: Partly verified
Materials actually read: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt.
Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified.
Reason for missing information: Full text, registration, plans and additional materials have not been acquired/read; existing content review remains incomplete.
Required materials and conditions: Stored summary, external paper/registration/plans/quality/harms slots and update events
Materials to obtain first: Original or correction material provided or separately authorized by the user
Further research: Material needed: Original or correction material provided or separately authorized by the user. This records needed materials; no new research was executed.
Remaining uncertainty: Gaps remain in actual composition, use, cancer treatment, oral care, measurement, prespecified endpoints, mITT/PP, between-group effects/intervals, missingness, support and harms. Original verdicts and historical verification wording do not constitute current external original-source reading or new clinical certification.
Conditions for verification: Original records on Stored summary, external paper/registration/plans/quality/harms slots and update events must link to formulation, actual use, population, comparison, WHO severity/onset, analyses, denominators and timepoints, distinguishing stored information from what remains unverified.
Why this condition is needed: Material on Stored summary, external paper/registration/plans/quality/harms slots and update events is needed to connect the relevant mouthwash, radiotherapy population, active comparator, selected severity outcome, separate onset outcome, analysis denominator or harm scope.
Application exceptions: Mouthwash remains distinct from swallowed formulations and gels for other oral conditions; delayed onset is not relabeled as prevention of severe mucositis. Doses are not calculated from concentrations, and allocation totals are not reused as group, analysis or harm denominators. No significant difference does not establish equivalence, noninferiority or complete ineffectiveness.
Referenced methods: Existing principles distinguish formulation, concentration, preparation, topical route, population, concurrent treatment, active comparator, WHO severity, onset, analysis denominators, support and harms in the retained mouthwash-trial record.

Related sources R01